Moderna

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-01-01

Employees: 5.6K

Market Cap: $30.3B

Website: http://www.modernatx.com

Introduction: Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: mRNA-1273.214
Biological: Placebo

First Posted Date: 2021-03-15

Last Posted Date: 2024-07-08

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 11950

Registration Number: NCT04796896

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
West Houston Clinical Research - Hunt, Houston, Texas, United States
🇺🇸
Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States

and more 87 locations

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: Placebo
Biological: mRNA-1273.222

First Posted Date: 2020-12-02

Last Posted Date: 2024-10-22

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 4331

Registration Number: NCT04649151

Locations: 🇺🇸
Velocity Clinical Research - Banning, Banning, California, United States
🇺🇸
Paradigm Clinical Research, La Mesa, California, United States
🇺🇸
Altus Research - Hunt - PPDS, Lake Worth, Florida, United States

and more 49 locations

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Phase 1

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: mRNA-1345
Drug: Placebo

First Posted Date: 2020-08-27

Last Posted Date: 2024-08-07

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 651

Registration Number: NCT04528719

Locations: 🇺🇸
Velocity Clinical Research - Medford - ERN - PPDS, Medford, Oregon, United States
🇺🇸
Flourish Research - San Antonio - PPDS, San Antonio, Texas, United States
🇺🇸
DM Clinical Research, Tomball, Texas, United States

and more 28 locations

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273
Biological: Placebo

First Posted Date: 2020-07-14

Last Posted Date: 2024-03-21

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 30415

Registration Number: NCT04470427

Locations: 🇺🇸
Synexus - Optimal Research - Rockville, Rockville, Maryland, United States
🇺🇸
UCLA Vine Street Clinic CRS, Los Angeles, California, United States
🇺🇸
VA Greater Los Angeles Healthcare (veterans only), Los Angeles, California, United States

and more 87 locations

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273.351
Biological: Placebo

First Posted Date: 2020-05-28

Last Posted Date: 2022-12-30

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 660

Registration Number: NCT04405076

Locations: 🇺🇸
Trial Management Associates, Wilmington, North Carolina, United States
🇺🇸
Meridian Clinical Research, Dakota Dunes, South Dakota, United States
🇺🇸
Benchmark Research, San Angelo, Texas, United States

and more 1 locations

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Phase 2

Completed

Conditions: Cytomegalovirus Infection

Interventions: Other: Placebo
Biological: mRNA-1647

First Posted Date: 2020-01-18

Last Posted Date: 2024-01-03

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 315

Registration Number: NCT04232280

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Crossroads Clinical Research, Victoria, Texas, United States

and more 6 locations

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Phase 1

Recruiting

Conditions: Propionic Acidemia

Interventions: Biological: mRNA-3927

First Posted Date: 2019-11-12

Last Posted Date: 2024-12-27

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 68

Registration Number: NCT04159103

Locations: 🇯🇵
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
🇯🇵
Tohoku University Hospital, Sendai-Shi, Miyagi, Japan
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 14 locations

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Phase 1

Completed

Conditions: Human Metapneumovirus and Human Parainfluenza Infection

Interventions: Biological: Placebo
Biological: mRNA-1653

First Posted Date: 2019-10-30

Last Posted Date: 2023-02-03

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 51

Registration Number: NCT04144348

Locations: 🇺🇸
Child Healthcare Associates, Liverpool, New York, United States
🇺🇸
Ohio Pediatric Research Assn Inc, Dayton, Ohio, United States
🇺🇸
UHS Primary Care, Binghamton, New York, United States

and more 13 locations

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Phase 1

Completed

Conditions: Zika Virus

Interventions: Other: Placebo
Biological: mRNA-1893

First Posted Date: 2019-08-22

Last Posted Date: 2024-08-21

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 120

Registration Number: NCT04064905

Locations: 🇵🇷
Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico
🇺🇸
Benchmark Research, Fort Worth, Texas, United States
🇺🇸
Meridan Clinical Research, Omaha, Nebraska, United States

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Drug: mRNA-4157
Biological: Pembrolizumab

First Posted Date: 2019-04-01

Last Posted Date: 2024-06-03

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 267

Registration Number: NCT03897881

Locations: 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇦🇺
Affinity Clinical Research, Murdoch, Western Australia, Australia
🇺🇸
UPMC Hillman Cancer Center, Chicago, Illinois, United States

and more 18 locations

Home Terms & Conditions Privacy Policy